NCT04893811 - Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 18, 2021

Primary Completion Date

September 6, 2023

Study Completion Date

September 6, 2023

Conditions

Meningococcal Vaccine

Interventions

BIOLOGICAL

Trumenba

Bivalent recombinant lipoprotein 2086 vaccine

Trial Locations (14)

Mersin Universitesi Tip Fakultesi Hastanesi, Mersin

Fakultni Nemocnice Brno - Detska Nemocnice - Klinika Detskych Infekcnich Nemoci Center 3, Brno

Fakultni Nemocnice Brno - Detska Nemocnice - Klinika Detskych Infekcnich Nemoci Center 3, Brno

Fakultni nemocnice v Motole, Prague

IN-VIVO Sp. z o.o., Bydgoszcz

Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o., Krakow

WIP Warsaw IBD Point Profesor Kierkus, Warsaw

Szpital Bielański im. Ks. Jerzego Popiełuszki SPZOZ, Warsaw

Baskent Universitesi Dr. Turgut Noyan Adana Uygulama ve Arastirma Merkezi, Adana

Baskent Universitesi Dr. Turgut Noyan Adana Uygulama ve Arastirma Merkezi, Adana

Acibadem Adana Hastanesi, Adana

Baskent Universitesi Dr. Turgut Noyan Adana Uygulama ve Arastirma Merkezi, Adana

Hacettepe Universitesi Tip Fakultesi, Ankara